Evaluation of peripheral blood inflammatory biomarkers in sickle cell disease with and without retinopathy.

Autor: Özer Ö; Department of Ophthalmology, Niğde Ömer Halisdemir University, Niğde, 51240, Turkey. omerozer92@gmail.com., Doğan L; Department of Ophthalmology, Niğde Ömer Halisdemir University, Niğde, 51240, Turkey., Baysal Z; Department of Ophthalmology, Niğde Ömer Halisdemir University, Niğde, 51240, Turkey., Basir H; Clinic of Internal Medicine, Gülnar State Hospital, Mersin, Turkey., Çıftçı AT; Department of Biostatistics and Medical Informatics, Niğde Ömer Halisdemir University, Niğde, Turkey., Eröz P; Clinic of Ophthalmology, Tarsus State Hospital, Mersin, Turkey., Güçlü ES; Clinic of Ophthalmology, Mersin State Hospital, Mersin, Turkey.
Jazyk: angličtina
Zdroj: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie [Graefes Arch Clin Exp Ophthalmol] 2024 Dec; Vol. 262 (12), pp. 3787-3796. Date of Electronic Publication: 2024 Jul 08.
DOI: 10.1007/s00417-024-06569-9
Abstrakt: Background: The aim of this study was to evaluate the clinical significance of blood-cell associated inflammation markers in patients with sickle cell disease (SCD) and sickle cell retinopathy (SCR).
Methods: Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to lymphocyte ratio (MLR), systemic immune inflammation index (SIII), systemic inflammation response index (SIRI), systemic inflammation modulation index (SIMI) and aggregate systemic inflammation index (AISI) were calculated. This study included 45 healthy controls (Group 1) and 100 SCD (Group 2). Patients in Group 2 were then divided into two groups: without SCR (Group 3) and with SCR (Group 4), and patients with SCR (Group 4) were further divided into two groups: non-proliferative sickle cell retinopathy (NPSCR) (Group 5) and proliferative sickle cell retinopathy (PSCR) (Group 6).
Results: The mean values for NLR, PLR, SIII, SIRI, AISI, and SIMI were significantly higher in Group 2 compared to Group 1 (p = 0.011 for NLR, p = 0.004 for SIII, and p < 0.001 for others). Furthermore, AISI and SIMI parameters demonstrated statistically significant discriminatory power to distinguish Group 5 from Group 6 (p = 0.0016 and p = 0.0006, respectively).
Conclusion: Given the critical role of inflammatory mechanisms in the pathogenesis of SCD and its related complications, the assessment of blood-cell-associated inflammatory markers may present a pragmatic and advantageous approach to the clinical oversight and therapeutic intervention of SCD.
Competing Interests: Declarations. Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the (Niğde Ömer Halisdemir University Clinical Research Ethics Committee No:2023/113) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent: Informed consent was obtained from all individual participants included in the study. Conflicts of interest: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honorar?ia; educational grants; participation in speakers? bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-finan?cial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: